Back to top
more

Biogen Inc. (BIIB)

(Real Time Quote from BATS)

$325.30 USD

325.30
882,847

-1.06 (-0.33%)

Updated Jul 23, 2021 03:59 PM ET

After-Market: $325.35 +0.05 (0.02%) 4:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (200 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 24.29% and 6.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $324.62 in the latest trading session, marking a -1.08% move from the prior day.

FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More

The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Lilly (LLY) Stock Riding on Pipeline Developments This Year

Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

Ekta Bagri headshot

3 Biotech Stocks Poised to Gain in the Second Half of 2021

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status

Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.

Cassava (SAVA) Stock Up on Alzheimer's Candidate Update

Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.

Here's Why Prothena (PRTA) Stock Is Up So Far This Month

Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.

Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

Sweta Jaiswal, FRM headshot

Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight

The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.

Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

Neena Mishra headshot

Should You Buy Biotech ETFs Now?

Biotech stocks are rallying this month; can the trend continue?

Sage Stock Declines on Late-Stage Depression Study Data

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal

Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.

Sweta Killa headshot

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.